As the abundance of DCK determines the tumor killing effect of oxidized methylcytidines in a DCTD-dependent manner, expression analysis of components of the DCK-DCTD axis in patients would provide a useful biomarker in cancer therapeutic applications of 5hmdC and 5fdC. This evidence concerns the gene DCTD and neoplasm.